Biogen Idec Inc (BIIB)

BIIB (NASDAQ:Drugs)
$306.74
pos +3.19
+1.05%
Today's Range: 304.78 - 308.84 | BIIB Avg Daily Volume: 1,341,900
Last Update: 11/24/14 - 4:00 PM EST
Volume: 1,384,196
YTD Performance: 6.99%
Open: $305.61
Previous Close: $303.55
52 Week Range: $270.27 - $358.89
Oustanding Shares: 236,155,407
Market Cap: 70,634,082,234
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 10 11 11
Moderate Buy 1 1 1 1
Hold 5 6 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.65 1.76 1.65 1.65
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 28.32
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
28.32 28.30 25.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-12.69% 23.33% 177.84%
GROWTH 12 Mo 3 Yr CAGR
Revenue 32.60 0.47 0.14
Net Income 34.90 1.07 0.27
EPS 35.70 0.97 0.25
Earnings for BIIB:
EBITDA 1.90B
Revenue 5.81B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $3.69 $n.a. $13.42 $16.77
Number of Analysts 1 0 1 1
High Estimate $3.69 $n.a. $13.42 $16.77
Low Estimate $3.69 $n.a. $13.42 $16.77
Prior Year $2.33 $2.45 $8.93 $13.42
Growth Rate (Year over Year) 58.37% n.a.% 50.28% 24.96%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Nov 14, 2014 | 6:31 PM EST

It's amazing how stupid the market really is.

By

Jim Cramer

 | Oct 30, 2014 | 2:31 PM EDT

Still, it's a good time to review what's happening, so we never forget.

By

Kate Stalter

 | Oct 30, 2014 | 2:00 PM EDT

Some growth leaders in the sector are getting technical support.

bearishBiogen Idec numbers cut at Nomura

Oct 23, 2014 | 6:43 AM EDT

Shares of BIIB now seen reaching $407, according to Nomura. Estimates also reduced, as Avonex is facing increased competition. Buy rating. 

By

Dick Arms

 | Sep 25, 2014 | 7:00 AM EDT

Use one short and one buy.

updateMorgan Stanley Healthcare Conf.

Sep 8, 2014 | 7:12 AM EDT

Morgan Stanley Healthcare Conference

By

Timothy Collins

 | Aug 26, 2014 | 11:54 AM EDT
Checking two biotech charts.
By

Jim Cramer

 | Aug 13, 2014 | 1:18 PM EDT

Biotech stocks are thriving in a slower-growth, low-inflation world.

By

Doug Kass

 | Aug 12, 2014 | 12:58 PM EDT
Take the ice bucket challenge?
By

Scott Redler

 | Aug 7, 2014 | 7:41 PM EDT

As the action continues to the downside, we have no long positions on the table.

Market starts the week with all indices ending up as the S&P posts 46th new high of th...
Shares of Exxon Mobil (XOM) have formed multiple basing patterns on the daily chart over t...
Conclusion BBRY stock is up 67% in the last year. The stock is also down 95% from its all...

$PANW delivers a perfect number but it might not be enough!!expensive...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.